Sign In
Buy MLTX
$19.02
-0.340 (-1.76%)
At Close: Jul 24, 2026
Biotech Fund BVF Trims MoonLake Stake, Sells $63M in Shares
02:07pm, Tuesday, 07'th Apr 2026
BVF sold 3,750,000 shares for a transaction value of approximately $62.96 million on April 2, 2026. The sale represented 78.30% of BVF's direct holdings, reducing direct ownership to 1,039,238 shares.
ZUG, Switzerland, March 28, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (MoonLake or the Company), a clinical-stage biotechnology company focused on creating next-level therapies for inflammat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Up After Analyst Upgrade
01:32am, Friday, 20'th Mar 2026
MoonLake Immunotherapeutics (NASDAQ: MLTX - Get Free Report) gapped up prior to trading on Thursday after Rothschild and Co Redburn upgraded the stock from a neutral rating to a buy rating. The stock
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know?
07:36pm, Monday, 16'th Mar 2026
Cormorant Asset Management increased its MoonLake Immunotherapeutics position by 2,361,260 shares in the fourth quarter; the estimated trade value is $27.86 million based on average quarterly prices.
Avoro Capital Advisors LLC Cuts Stock Position in MoonLake Immunotherapeutics $MLTX
03:07am, Saturday, 14'th Mar 2026
Avoro Capital Advisors LLC lessened its holdings in shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) by 51.8% in the undefined quarter, according to the company in its most recent 13F filing with
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of “Hold” from Analysts
02:50am, Friday, 13'th Mar 2026
MoonLake Immunotherapeutics (NASDAQ: MLTX - Get Free Report) has been assigned a consensus recommendation of "Hold" from the sixteen analysts that are presently covering the firm, MarketBeat Ratings r
Uniqure To Rally Around 92%? Here Are 10 Top Analyst Forecasts For Wednesday
08:19am, Wednesday, 11'th Mar 2026
Top Wall Street analysts changed their outlook on top names. See all changes on analyst ratings page.
MoonLake: Downgrade To Buy As Sonelokimab Still Has A BLA Shot On Goal
01:50pm, Tuesday, 24'th Feb 2026
MoonLake Immunotherapeutics is downgraded from Strong Buy to Buy following a mixed phase 3 outcome for sonelokimab in hidradenitis suppurativa [HS]. Despite VELA-2's primary endpoint miss, the FDA's p
MoonLake Immunotherapeutics Investor Day: HS BLA on Track, axSpA Phase 2 Data Highlights Imaging Wins
01:16am, Tuesday, 24'th Feb 2026
MoonLake Immunotherapeutics (NASDAQ: MLTX) used its Investor Day presentation to outline updates across its clinical portfolio for sonelokimab (SLK), a tri-specific nanobody designed to inhibit IL-17A
MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript
03:24pm, Monday, 23'rd Feb 2026
MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript
MoonLake Immunotherapeutics Data Shows Phase 2 Success For Chronic Back Pain
09:10am, Monday, 23'rd Feb 2026
Axial Spondyloarthritis is a chronic, immune-mediated inflammatory disease mainly affecting the spine and sacroiliac joints, often causing chronic back pain, stiffness, and potential spinal fusion.
In the Phase 2 S-OLARIS clinical trial in axial spondyloarthritis (axSpA), sonelokimab (SLK) demonstrated clinically meaningful benefit with 80% of patients achieving ASAS40 by Week 12 Consistently, o
Principal Financial Group Inc. Invests $509,000 in MoonLake Immunotherapeutics $MLTX
03:21am, Friday, 20'th Feb 2026
Principal Financial Group Inc. purchased a new stake in MoonLake Immunotherapeutics (NASDAQ: MLTX) in the third quarter, according to the company in its most recent Form 13F filing with the Securities
ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer
07:00am, Tuesday, 10'th Feb 2026
Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene's clinical organization and drive compl
BioTech Breakout: MoonLake Up 30% On FDA Wins
03:48pm, Tuesday, 03'rd Feb 2026
In a stock market currently obsessed with interest rate cuts and the artificial intelligence (AI) boom, it is easy to overlook the biotechnology sector. However, for investors willing to look beyond t
